26.08.2010 • News

Sanofi Won't Go Above $70 per Share for Genzyme

Sanofi-Aventis is not willing to pay more than $70 per share for U.S. biotech Genzyme and may look at alternative targets, Bloomberg reported on Wednesday, citing sources familiar with the matter.

France's Sanofi has offered $69 per share for Genzyme and its board has authorized a bid of up to $70 per share, sources have told press representatives in the past.

According to the Bloomberg report, Sanofi may consider companies such as Bausch & Lomb, Allergan or Celgene if a deal with Genzyme falls through.

Interview

Driving Sustainability Through Collaboration
Building Green Practices Across the Chemical Supply Chain

Driving Sustainability Through Collaboration

Together for Sustainability (TfS) is a pioneering, member-led initiative working to accelerate sustainable and resilient chemical supply chains. TfS President Jennifer Jewson discusses the origins of TfS, its evolving goals, its present-day challenges, and the initiative’s enduring impact and outlook for the future.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Top-Feature

most read